BC Extra | Sep 15, 2015
Financial News

Acacia plans L150M IPO

Acacia Pharma Ltd. (Cambridge, U.K.) plans to raise L150 million ($232 million) in an IPO on the London Stock Exchange in October, according to a person familiar with the company. JPMorgan Cazenove and Canaccord are...
BC Extra | Oct 8, 2014
Clinical News

Acacia seeks options after hitting in PONV Phase III

Acacia Pharma Ltd. (Cambridge, U.K.) said its lead product APD421 reduced the incidence of post-operative nausea and vomiting in two Phase III trials of adult surgical patients at moderate to high risk for PONV. Acacia,...
BC Innovations | Aug 21, 2014
Cover Story

Fat chance for cancer cachexia

With no drugs on the market and a pair of recent Phase III failures in cancer-associated cachexia, companies could be better off turning to the cause of the wasting disease rather than targeting its symptoms....
BioCentury | Jun 18, 2012
Product Development

Acacia's upside bonus

Acacia Pharma Ltd. was searching for a safer version of droperidol , which is efficacious in preventing postoperative nausea and vomiting but not often used due to safety issues. Now Phase II data show APD421 actually...
BC Week In Review | Dec 12, 2011
Clinical News

APD209: Phase IIa data

A U.K. Phase IIa trial in 7 evaluable cancer patients showed that APD209 for 8 weeks led to a major response, defined as an increase of >=4% in quadriceps muscle size and/or a >=10% increase...
BioCentury | Mar 2, 2009
Emerging Company Profile

Acacia: Fishing for support

Acacia Pharma Ltd. is applying the reprofiling model to hospital-based supportive care with an initial focus on cancer, a market the company says has limited competition and a low cost of development relative to primary...
Items per page:
1 - 6 of 6